Literature DB >> 30722840

Hematological Malignancies in Adults With a Family Predisposition.

Tilmann Bochtler1, Georg-Martin Haag, Sarah Schott, Matthias Kloor, Alwin Krämer, Carsten Müller-Tidow.   

Abstract

BACKGROUND: Some hematological malignancies arise in persons with a hereditary predisposition. The hereditary nature of these diseases often goes unrecognized, particularly when symptoms begin in adulthood.
METHODS: This review is based on pertinent publications retrieved by a selective search in PubMed.
RESULTS: Many rare germline mutations have been identified that lead to acute leukemia and myelodysplastic syndromes. They differ from one another with respect to their penetrance, the age of onset of disease, and the clinical manifestations. In view of this heterogeneity, no uniform recommendations have yet been formulated for their diagnosis and treatment. The most common types of hematological malig- nancy with a hereditary predisposition are traceable to an underlying disturbance of DNA damage response and repair mechanisms and to mutations of hematological transcription factors. With regard to the selection of patients for testing, the con- sensus is that cytogenetic and molecular-genetic findings that are suspect for a hereditary predisposition, such as CEBPA and RUNX1 mutations, call for further investigation, as do any clinical features that are typical of tumor syndromes, or a positive family history. The knowledge that a hereditary predisposition may be present is highly stressful for patients; testing should only be carried out after the patient has received genetic counseling. The confirmation of a germline mutation always requires a comparison with healthy tissue. A fibroblast culture is recom- mended as the gold standard for this purpose.
CONCLUSION: The detection of a hereditary predisposition to hematological neoplasia is often relevant to treatment and follow-up care: for example, it may motivate early allogeneic stem-cell transplantation. Counseling, predictive testing, and follow-up care are available to the patients' relatives as well.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30722840      PMCID: PMC6375069          DOI: 10.3238/arztebl.2018.0848

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN: 1866-0452            Impact factor:   5.594


  71 in total

1.  Further evidence that germline CEBPA mutations cause dominant inheritance of acute myeloid leukaemia.

Authors:  G S Sellick; H E Spendlove; D Catovsky; K Pritchard-Jones; R S Houlston
Journal:  Leukemia       Date:  2005-07       Impact factor: 11.528

2.  Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline 'de-novo' TP53 mutation.

Authors:  A Salmon; D Amikam; N Sodha; S Davidson; L Basel-Vanagaite; R A Eeles; D Abeliovich; T Peretz
Journal:  Clin Oncol (R Coll Radiol)       Date:  2007-06-14       Impact factor: 4.126

3.  Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation.

Authors:  Elisa Rumi; Francesco Passamonti; Matteo G Della Porta; Chiara Elena; Luca Arcaini; Laura Vanelli; Cecilia Del Curto; Daniela Pietra; Emanuela Boveri; Cristiana Pascutto; Mario Cazzola; Mario Lazzarino
Journal:  J Clin Oncol       Date:  2007-11-12       Impact factor: 44.544

4.  Mutation of CEBPA in familial acute myeloid leukemia.

Authors:  Matthew L Smith; Jamie D Cavenagh; T Andrew Lister; Jude Fitzgibbon
Journal:  N Engl J Med       Date:  2004-12-02       Impact factor: 91.245

5.  Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.

Authors:  Ola Landgren; Lynn R Goldin; Sigurdur Y Kristinsson; Elin A Helgadottir; Jan Samuelsson; Magnus Björkholm
Journal:  Blood       Date:  2008-05-01       Impact factor: 22.113

Review 6.  [Molecular pathology in hereditary colorectal cancer. Recommendations of the Collaborative German Study Group on hereditary colorectal cancer funded by the German Cancer Aid (Deutsche Krebshilfe)].

Authors:  J Rüschoff; B Roggendorf; F Brasch; M Mathiak; D E Aust; J Plaschke; W Mueller; C Poremba; M Kloor; G Keller; M Muders; S Blasenbreu-Vogt; P Rümmele; A Müller; R Büttner
Journal:  Pathologe       Date:  2004-05       Impact factor: 1.011

Review 7.  Familial chronic myeloproliferative disorders: the state of the art.

Authors:  Elisa Rumi
Journal:  Hematol Oncol       Date:  2008-09       Impact factor: 5.271

8.  Genetic heterogeneity among Fanconi anemia heterozygotes and risk of cancer.

Authors:  Marianne Berwick; Jaya M Satagopan; Leah Ben-Porat; Ann Carlson; Katherine Mah; Rashida Henry; Raffaella Diotti; Kelly Milton; Kanan Pujara; Tom Landers; Sat Dev Batish; José Morales; Detlev Schindler; Helmut Hanenberg; Robert Hromas; Orna Levran; Arleen D Auerbach
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701

9.  P53 germline mutations in childhood cancers and cancer risk for carrier individuals.

Authors:  A Chompret; L Brugières; M Ronsin; M Gardes; F Dessarps-Freichey; A Abel; D Hua; L Ligot; M G Dondon; B Bressac-de Paillerets; T Frébourg; J Lemerle; C Bonaïti-Pellié; J Feunteun
Journal:  Br J Cancer       Date:  2000-06       Impact factor: 7.640

10.  Analysis of PALB2/FANCN-associated breast cancer families.

Authors:  Marc Tischkowitz; Bing Xia; Nelly Sabbaghian; Jorge S Reis-Filho; Nancy Hamel; Guilan Li; Erik H van Beers; Lili Li; Tayma Khalil; Louise A Quenneville; Atilla Omeroglu; Aletta Poll; Pierre Lepage; Nora Wong; Petra M Nederlof; Alan Ashworth; Patricia N Tonin; Steven A Narod; David M Livingston; William D Foulkes
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-09       Impact factor: 11.205

View more
  5 in total

1.  Supplemental Human Genetics Point of View.

Authors:  Tim Ripperger; Thomas Illig; Brigitte Schlegelberger
Journal:  Dtsch Arztebl Int       Date:  2019-04-05       Impact factor: 5.594

2.  In Reply.

Authors:  Tilmann Bochtler
Journal:  Dtsch Arztebl Int       Date:  2019-04-05       Impact factor: 5.594

Review 3.  Prognostic Markers of Myelodysplastic Syndromes.

Authors:  Yuliya Andreevna Veryaskina; Sergei Evgenievich Titov; Igor Borisovich Kovynev; Tatiana Ivanovna Pospelova; Igor Fyodorovich Zhimulev
Journal:  Medicina (Kaunas)       Date:  2020-07-27       Impact factor: 2.430

4.  Patterns of Bone Marrow Confirmed Malignant and Non-Malignant Hematological Disorders in Patients with Abnormal Hematological Parameters in Northeast Ethiopia.

Authors:  Hussen Ebrahim; Temesgen Fisha; Habtu Debash; Habtye Bisetegn
Journal:  J Blood Med       Date:  2022-02-15

5.  Meiotic drive in chronic lymphocytic leukemia compared with other malignant blood disorders.

Authors:  Viggo Jønsson; Haneef Awan; Neil Deaton Jones; Tom Børge Johannesen; Klaus Thøgersen; Bjarni Á Steig; Gudrid Andorsdottir; Geir Erland Tjønnfjord
Journal:  Sci Rep       Date:  2022-04-12       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.